PeptideCompareCerluten — EU research guide.
Cerluten is a synthetic tripeptide (Peptide complex (cytomedine)) from the Khavinson bioregulator series proposed to act on nervous system gene regulation. It sits in the same family as Pinealon, which PeptideCompare already tracks, and is frequently discussed alongside it in Eastern European longevity research.
What is Cerluten?
Cerluten is a synthetic tripeptide (Peptide complex (cytomedine)) from the Khavinson bioregulator series proposed to act on nervous system gene regulation. It sits in the same family as Pinealon, which PeptideCompare already tracks, and is frequently discussed alongside it in Eastern European longevity research.
What does the research show?
No peer-reviewed study of Cerluten itself could be verified; the neuronal gene-expression and animal work published by the originating group concerns defined short peptides such as EDR and KED, and claims of supporting nervous-system aging resilience have not been shown for Cerluten. As with other Khavinson bioregulators, independently replicated human clinical trial data is not publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available from a small number of specialist research peptide vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Cerluten is not yet in our price comparison
We expand EU supplier coverage every month.